Related references
Note: Only part of the references are listed.Randomized, Placebo-Controlled Trial of ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 3)
Wolfgang Oertel et al.
MOVEMENT DISORDERS (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) A Randomized Clinical Trial
Rajesh Pahwa et al.
JAMA NEUROLOGY (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
Rajesh Pahwa et al.
MOVEMENT DISORDERS (2015)
ATLAS OF MULTIPLE SCLEROSIS 2013: A GROWING GLOBAL PROBLEM WITH WIDESPREAD INEQUITY
Paul Browne et al.
NEUROLOGY (2014)
Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis - result of a pilot randomized, blind study
Alenka Horvat Ledinek et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2013)
Effects of antagonists of glutamate receptors on pro-inflammatory cytokines in the brain cortex of rats subjected to experimental autoimmune encephalomyelitis
Grzegorz Sulkowski et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Disability in multiple sclerosis A reference for patients and clinicians
Ilya Kister et al.
NEUROLOGY (2013)
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis
Silvia Rossi et al.
PLOS ONE (2013)
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation
Ralph H. B. Benedict et al.
BMC NEUROLOGY (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis
Andrew D. Goodman et al.
ANNALS OF NEUROLOGY (2010)
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
Andrew D. Goodman et al.
LANCET (2009)
The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue
I. K. Penner et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Patient perception of bodily functions in multiple sclerosis:: gait and visual function are the most valuable
C. Heesen et al.
MULTIPLE SCLEROSIS (2008)
Temporal trends in the incidence of multiple sclerosis
Alvaro Alonso et al.
NEUROLOGY (2008)
Assessing walking ability in subjects with spinal cord injury: Validity and reliability of 3 walking tests
HJ van Hedel et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2005)
Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial
V Tomassini et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2004)
Measuring the impact of MS on walking ability - The 12-Item MS Walking Scale (MSWS-12)
JC Hobart et al.
NEUROLOGY (2003)
Share Paper
